UpGuard's Cyber Security Ratings range from 0 to 950. The higher the score, the more likely Agios is implementing good security practices.
Agios Pharmaceuticals Inc. is a public American pharmaceutical company focused on developing small-molecule anti-cancer therapeutics targeting cancer cell metabolism via the growth factor pathway. Among the proteins under investigation by the company are IDH1 and IDH2. The company was founded in 2008 (or 2007) by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013.
This report shows a preliminary security rating for Agios. UpGuard scans billions of digital assets daily, in depth, across thousands of vectors. Data leak detection, vulnerability scanning and identity breach detection are just some of the advanced capabilities offered by the UpGuard platform.Get a deeper scan →
Read more about the latest issues in cybersecurity
Business units are outsourcing more of their operations to third-party suppliers. In turn, these ...
Third-party vendors are an important source of strategic advantage, cost savings and expertise. Yet ...
Compare Agios's security performance with other companies